A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
Recruiting now
Conditions studied: Paroxysmal Nocturnal Hemoglobinuria
In brief
The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients. Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH.
Key facts
- Study ID
- NCT06931691
- Run by
- Novartis Pharmaceuticals
- People needed
- 80
- Starts
- 2025-06-10
- Expected to finish
- 2027-04-21
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Hefei, Anhui, China (enrolling)
- Novartis Investigative Site — Guangzhou, Guangdong, China (enrolling)
- Novartis Investigative Site — Guangzhou, Guangdong, China (enrolling)
- Novartis Investigative Site — Shijiazhuang, Hebei, China (enrolling)
- Novartis Investigative Site — Zhengzhou, Henan, China (enrolling)
- Novartis Investigative Site — Zhengzhou, Henan, China (enrolling)
- Novartis Investigative Site — Wuhan, Hubei, China (enrolling)
- Novartis Investigative Site — Nantong, Jiangsu, China (enrolling)
- Novartis Investigative Site — Nanchang, Jiangxi, China (enrolling)
- Novartis Investigative Site — Changchun, Jilin, China (enrolling)
- Novartis Investigative Site — Jinan, China (enrolling)
- Novartis Investigative Site — Tianjin, China (enrolling)
- Novartis Investigative Site — Tianjin, China (enrolling)
- Novartis Investigative Site — Wuhan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.